HeartSciences Files Comprehensive Merger Proxy: 95% Dilution, Nasdaq Deficiency, and Reverse Split Details
HSCS has more than doubled off its 52-week low of $1.63 on light trading volume (0.2× avg).
Summary
HeartSciences' merger proxy reveals existing shareholders will own just 5% of the combined company, with DCG's Fortitude taking 95% control. The filing also discloses a Nasdaq delisting notice and a proposed reverse stock split to maintain listing.
Key Events · M&A and Partnerships · HSCS
-
95% Dilution for Existing Shareholders
Fortitude Seller (DCG subsidiary) will own approximately 95% of the combined company's voting interests, leaving existing HeartSciences shareholders with only 5% economic and voting interest in Class A Common Stock.
-
Nasdaq Delisting Deficiency
HeartSciences received a Nasdaq deficiency letter on August 4, 2026 for failing to maintain $2.5M minimum stockholders' equity. The company must submit a compliance plan by September 18, 2026 — the same date as this filing.
-
Reverse Stock Split Proposed
Proposal 4 seeks approval for a reverse stock split of 1-for-2 to 1-for-5 to meet Nasdaq's $4.00 minimum bid price requirement for the combined company's initial listing.
-
August 2026 PIPE Investment
Fortitude Seller purchased 411,522 shares at $2.43 per share on August 12, 2026 for approximately $1.0 million in gross proceeds, giving Fortitude approximately 9.4% ownership of HeartSciences pre-merger.
Analysis · HSCS · Crypto Assets
This preliminary proxy statement is the definitive disclosure document for the Fortitude Mining merger, revealing that existing HeartSciences shareholders will be diluted to approximately 5% ownership while Fortitude Seller (DCG) takes 95% voting control. The filing also discloses a Nasdaq delisting deficiency with a September 18, 2026 compliance deadline — the same day as this filing — and a proposed reverse stock split of 1-for-2 to 1-for-5 to meet listing requirements. The August 2026 PIPE Investment of $1.0 million at $2.43 per share (vs. today's $4.76) provided bridge funding but further diluted existing holders. The board unanimously recommends approval, citing liquidation as the alternative if the merger fails.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.5% of the 373 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HSCS was trading at $4.76 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $23.2M. The 52-week trading range was $1.63 to $4.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.